atrial fibrillation - prevention - patients without history of AF (primary prevention) clinical trials results meta-analysis

<h1> <a href="TM10-120-prevention-atrial fibrillation" > <strong>atrial fibrillation</strong> - prevention </a> - patients without history of AF (primary prevention) trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t9791.htm"> ARMYDA-3, 2006 </a> <br> </td> <td> atorvastatin 40mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with scheduled cardiac surgery without history of AF </td> <td> follow-up 30 days<br> n=101/99<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9792.htm"> Chello, 2006 </a> <br> </td> <td> atorvastatin 20mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with scheduled coronary bypass surgery </td> <td> follow-up 3 weeks<br> n=20/20<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9793.htm"> MIRACL, 2001 </a> <br> </td> <td> atorvastatin 80mg daily<br>  <i>versus</i> <br> placebo </td> <td> Acute coronary syndrome; subgroup without history of AF </td> <td> follow-up 16 weeks<br> n=1421/1440<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9794.htm"> TRACE, 1999 </a> <br> </td> <td> trandolapil<br>  <i>versus</i> <br> placebo </td> <td> Post–myocardial infarction </td> <td> follow-up 2.4 y<br> n=790/787<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9795.htm"> SOLVD, 2003 </a> <br> </td> <td> enalapril<br>  <i>versus</i> <br> placebo </td> <td> Heart failure </td> <td> follow-up 2.9 y<br> n=186/188<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9796.htm"> GISSI-3, 2003 </a> <br> </td> <td> lisinopril<br>  <i>versus</i> <br> placebo </td> <td> Post–myocardial infarction </td> <td> follow-up 0.5 y<br> n=8902/8846<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9797.htm"> Val-HeFT, 2003 </a> <br> </td> <td> valsartan<br>  <i>versus</i> <br> placebo </td> <td> Heart failure </td> <td> follow-up 1.92 y<br> n=2506/2494<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9798.htm"> LIFE, 2005 </a> <br> </td> <td> losartan<br>  <i>versus</i> <br> atenolol </td> <td> hypertension </td> <td> follow-up 4.8 y<br> n=4298/4182<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9799.htm"> CHARM, 2005 </a> <br> </td> <td> candesartan<br>  <i>versus</i> <br> placebo </td> <td> Heart failure </td> <td> follow-up 3.17 y<br> n=3225/3221<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9804.htm"> VA HIT, 1999 </a> <br> </td> <td> gemfibrozil<br>  <i>versus</i> <br> placebo </td> <td> men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less </td> <td> follow-up 4.4 y<br> n=1070/1060<br> Parallel groups<br> double blind <br> US </td> </tr> <tr> <td> <a href="../TRC_t9896.htm"> GISSI HF (subgroup and ancillary study), 2009 </a> <br> NCT00336336 </td> <td> rosuvastatin 10mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with chronic heart failure who were not in AF at study entry </td> <td> follow-up 3.7y (median)<br> n=1855/1835<br> Factorial plan<br> double-blind <br> Italy </td> </tr> </table> <h2>References</h2> <p> <b>ARMYDA-3, 2006 : </b> Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio GRandomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. <i>Circulation 2006;114:1455-61</i> [PMID 17000910] 10.1161/CIRCULATIONAHA.106.621763 </p> <p> <b>Chello, 2006 : </b> Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, Carassiti M, Covino EEffects of atorvastatin on systemic inflammatory response after coronary bypass surgery. <i>Crit Care Med 2006;34:660-7</i> [PMID 16505650] 10.1097/01.CCM.0000201407.89977.EA </p> <p> <b>MIRACL, 2001 : </b> Schwartz GG, Olsson AG, Chaitman B, Goldberger J, Szarek M, <i>Circulation 2004;110 Suppl:S740</i> [PMID ] </p> <p> <b>MIRACL, 2001 : </b> Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern TEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. <i>JAMA 2001;285:1711-8</i> [PMID 11277825] </p> <p> <b>TRACE, 1999 : </b> Pedersen OD, Bagger H, Kober L, Torp-Pedersen CTrandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. <i>Circulation 1999;100:376-80</i> [PMID 10421597] </p> <p> <b>SOLVD, 2003 : </b> Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme AEnalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. <i>Circulation 2003;107:2926-31</i> [PMID 12771010] 10.1161/01.CIR.0000072793.81076.D4 </p> <p> <b>GISSI-3, 2003 : </b> Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni GIncidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. <i>Heart 2001;86:527-32</i> [PMID 11602545] </p> <p> <b>Val-HeFT, 2003 : </b> Maggioni ALR, Carson PE, et alValsartan reduces the incidence of atrial fibrillation in the patients with heart failure in the Val-HeFT Trial <i>Circulation 2003;108:507</i> [PMID ] </p> <p> <b>LIFE, 2005 : </b> Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RBAngiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. <i>J Am Coll Cardiol 2005;45:712-9</i> [PMID 15734615] 10.1016/j.jacc.2004.10.068 </p> <p> <b>CHARM, 2005 : </b> McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MAEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet 2003;362:767-71</i> [PMID 13678869] 10.1016/S0140-6736(03)14283-3 </p> <p> <b>VA HIT, 1999 : </b> Adabag AS, Mithani S, Al Aloul B, Collins D, Bertog S, Bloomfield HEEfficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. <i>Am Heart J 2009;157:913-8</i> [PMID 19376321] </p> <p> <b>VA HIT, 1999 : </b> Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes JGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. <i>N Engl J Med 1999;341:410-8</i> [PMID 10438259] </p> <p> <b>GISSI HF (subgroup and ancillary study), 2009 : </b> Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, Tavazzi LEffects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. <i>Eur Heart J 2009 Oct;30:2327-36</i> [PMID 19717850] </p>